Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990
Classifica tra le azioni
#1584
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company,... Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Prezzo delle azioni
$57.07
Capitalizzazione di mercato
$13.64B
Variazione (1 giorno)
-5.37%
Variazione (1 anno)
-2.19%
Paese
CN
Scambia Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Categoria
Healthcare
Utile per Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990)
Utile nel Jun 2026 TTM: $7.37M
Secondo gli ultimi rapporti finanziari di Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., gli utili attuali della società sono $7.37M. Nel 2024, la società ha registrato un utile di $-19.53M, un aumento rispetto a agli utili del 2023, che erano di $-66.07M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. dal 2021 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $7.37M | -114.49% |
| 2025 | $-50.85M | 160.39% |
| 2024 | $-19.53M | -70.44% |
| 2023 | $-66.07M | -19.67% |
| 2022 | $-82.25M | -40.27% |
| 2021 | $-137.71M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | 71,494.49% |
US
|
|
| $-3.09B | -41,998.84% |
US
|
|
| $-4.02B | -54,610.52% |
AU
|
|
| $3.01B | 40,695.61% |
BE
|
|
| $1.95B | 26,375.53% |
NL
|
